Curanex Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Curanex Pharmaceuticals Inc. (Nasdaq: CURX) on November 6, 2025, reporting an event that occurred on November 5, 2025. The Company is a Nevada corporation headquartered in Jericho, NY, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the listing notice.
Material Changes
The Company received a notice from Nasdaq stating that for the last 30 consecutive business days, the closing bid price of its Common Stock was below the required minimum of $1.00 per share. This constitutes a failure to satisfy Nasdaq Listing Rule 5550(a)(2).
Outlook, Risks, and Contingencies
- Compliance Period: The Company has been granted an initial 180-calendar day compliance period ending May 4, 2026, to regain compliance.
- Regaining Compliance: Compliance is achieved if the closing bid price reaches at least $1.00 per share for a minimum of ten consecutive business days during the compliance period.
- Delisting Risk: If the Company fails to regain compliance, it may be eligible for an additional 180-day period if it meets market value requirements and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
- Immediate Effect: The notice has no immediate effect on the listing; the stock will continue to trade on The Nasdaq Capital Market under the symbol "CURX" pending compliance.
Investor Verification Checklist
- Verify the current closing bid price of CURX to assess proximity to the $1.00 threshold.
- Monitor the Company's announcements regarding a potential reverse stock split to cure the deficiency.
- Review the Company's market value of publicly held shares to determine eligibility for an additional compliance period if the initial 180 days expire without compliance.
- Check for any subsequent Nasdaq communications regarding extensions or delisting determinations.